Ares Financial Consulting’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ares Financial Consulting’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69K	Buy	+5	New	+$2.56K	﹤0.01%	841

Other funds holding MDGL

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.13B AUM 23.04% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Ares Financial Consulting's MDGL Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 5 shares worth $2.69K. The stake represents ﹤0.01% of the portfolio and ranks #841 among its holdings.

141 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Ares Financial Consulting held 5 shares of Madrigal Pharmaceuticals worth $2.69K as of Q2 2026.
Madrigal Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #841 holding.
141 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.